Sunday, November 22, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Rodolfo Hanigan by Rodolfo Hanigan
March 25, 2026
in Analysis, Healthcare, Pharma & Biotech
0
ImmunityBio Stock
0
SHARES
61
VIEWS
Share on FacebookShare on Twitter

A significant regulatory warning from the U.S. Food and Drug Administration (FDA) has triggered a sharp sell-off in ImmunityBio shares. The stock plummeted more than 25% at one point during Tuesday’s trading session following the agency’s action.

The Core of the FDA’s Complaint

The FDA issued a formal reprimand to the biotechnology firm over its promotional activities for the bladder cancer drug ANKTIVA. According to the regulator, the company’s television advertisements and podcast appearances improperly presented the therapy as a potential universal cure for all cancer types. This marketing, the FDA stated, created a public health risk by going far beyond the drug’s actual approved use.

ANKTIVA is specifically sanctioned for a narrowly defined patient group: those with BCG-resistant non-muscle invasive bladder cancer carcinoma in situ. The warning letter explicitly cited statements made by Executive Chairman Dr. Patrick Soon-Shiong and CEO Richard Adcock as central examples of the violations.

A Pattern of Marketing Violations

This incident marks the third such warning for ImmunityBio in a short period. Previous communications regarding marketing compliance failures were sent in September 2025 and January 2026, targeting both ImmunityBio and its subsidiary, Altor BioScience. The company now has 15 business days to formally respond to the latest letter and submit a comprehensive correction plan to the agency.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Analyst Perspective Amid the Turmoil

Despite the severe market reaction, some analysts maintain a constructive view. D. Boral Capital reaffirmed its buy rating on Monday, confirming a price target of $23.00 per share. The firm’s researchers pointed to the underlying therapeutic potential of ImmunityBio’s IL-15 superagonist platform, characterizing the marketing issues as a short-term obstacle.

The company’s operational backdrop presents a mixed picture. Recent developments include the National Comprehensive Cancer Network’s decision to add ANKTIVA to its treatment guidelines for papillary NMIBC on March 17. This was followed by the therapy’s first Asian approval in Macau on March 20. Furthermore, the ongoing QUILT-3.078 Phase 2 trial continues to evaluate ANKTIVA in a chemotherapy-free immunotherapy combination for recurrent glioblastoma.

The immediate challenge, however, remains regulatory. Three formal warnings from the FDA within six months suggest a persistent issue, and investors are now clearly pricing in the risk of a protracted conflict with the authority.

Ad

ImmunityBio Stock: Buy or Sell?! New ImmunityBio Analysis from November 22 delivers the answer:

The latest ImmunityBio figures speak for themselves: Urgent action needed for ImmunityBio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 22.

ImmunityBio: Buy or sell? Read more here...

Tags: ImmunityBio
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
Münchener Rück Stock
Analysis

Munich Re’s Monte Carlo Warning Collides With Wall Street’s Widest Analyst Split in Years

September 7, 2026
Novo Nordisk Stock
Analysis

Novo Nordisk Faces a New Front: 300-Fold Rise in GLP-1 Scripts for Children Under 12

September 7, 2026
Next Post
Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

Take-Two Stock

GTA VI Launch Date Sets Stage for Take-Two's Financial Horizon

Bionxt Solutions Stock

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

Recommended

WM stock news

Spire Wealth Management Shows Confidence in Churchill Downs Incorporated with New Acquisition and Bet on Future Growth

3 years ago
Chevron Stock

Chevron Shares Surge Amid Global Oil Supply Disruption

8 months ago
Q2 Holdings Stock

Inclusion in S&P SmallCap 600 Index Ignites Q2 Holdings Stock Rally

1 year ago
REV Stock

REV Group Shares Hit Record High Amid Political Scrutiny

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

Trending

CrowdStrike Stock
Newsletter

93% of Stocks Fall as CrowdStrike Courts Zscaler

by Stephanie Dugan
November 21, 2026
0

Dear readers, The question heading into Friday was whether Anthropic would hold its $83 offer price. It...

Nvidia Stock

Anthropic Lists at a Premium, but the Sell-Off Keeps Going

November 20, 2026
Bitcoin Stock

Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

November 19, 2026
Nvidia Stock

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

November 18, 2026
Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • 93% of Stocks Fall as CrowdStrike Courts Zscaler
  • Anthropic Lists at a Premium, but the Sell-Off Keeps Going
  • Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com